Longitudinal clinico-serological analysis of anti-nucleocapsid and anti-receptor binding domain of spike protein antibodies against SARS-CoV-2
Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved..
OBJECTIVES: Monitoring the antibody responses to SARS-CoV-2 infection and its correlation to clinical spectrum of disease is critical in understanding the disease progression and protection against re-infection. We assessed the nucleocapsid (N) and receptor-binding-domain of spike (SRBD) protein specific IgG and neutralizing antibody (NAb) responses in COVID-19 patients up to 8 months and its correlation with diverse disease spectrum.
METHODS: During the first wave of the SARS-CoV-2 pandemic, from 284 COVID-19 patients, 608 samples were collected up to 8 months post infection. The patients were categorized as asymptomatic, symptomatic and severe. The N and SRBD IgG and NAb titers were evaluated and correlated with clinical data.
RESULTS: A steep increase in antigen specific antibody titers was observed till 40 days post onset of the disease (POD), followed by a partial decline till 240 days. Severe disease was associated with a stronger SRBD IgG response and higher NAb titers. The persistence of antibody response was observed in 76% against N, 80% against SRBD and 80% for NAbs of cases up to 8 months POD.
CONCLUSION: RBD and N protein specific IgG persisted till 240 days POD which correlated with NAb response, irrespective of individual`s symptomatic status indicating overall robust protection against re-infection.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:112 |
|---|---|
| Enthalten in: |
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases - 112(2021) vom: 01. Nov., Seite 103-110 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Deshpande, Gururaj Rao [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 03.12.2021 Date Revised 31.05.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ijid.2021.09.024 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM330856499 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM330856499 | ||
| 003 | DE-627 | ||
| 005 | 20231225212205.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijid.2021.09.024 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1102.xml |
| 035 | |a (DE-627)NLM330856499 | ||
| 035 | |a (NLM)34543771 | ||
| 035 | |a (PII)S1201-9712(21)00732-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Deshpande, Gururaj Rao |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Longitudinal clinico-serological analysis of anti-nucleocapsid and anti-receptor binding domain of spike protein antibodies against SARS-CoV-2 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.12.2021 | ||
| 500 | |a Date Revised 31.05.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a OBJECTIVES: Monitoring the antibody responses to SARS-CoV-2 infection and its correlation to clinical spectrum of disease is critical in understanding the disease progression and protection against re-infection. We assessed the nucleocapsid (N) and receptor-binding-domain of spike (SRBD) protein specific IgG and neutralizing antibody (NAb) responses in COVID-19 patients up to 8 months and its correlation with diverse disease spectrum | ||
| 520 | |a METHODS: During the first wave of the SARS-CoV-2 pandemic, from 284 COVID-19 patients, 608 samples were collected up to 8 months post infection. The patients were categorized as asymptomatic, symptomatic and severe. The N and SRBD IgG and NAb titers were evaluated and correlated with clinical data | ||
| 520 | |a RESULTS: A steep increase in antigen specific antibody titers was observed till 40 days post onset of the disease (POD), followed by a partial decline till 240 days. Severe disease was associated with a stronger SRBD IgG response and higher NAb titers. The persistence of antibody response was observed in 76% against N, 80% against SRBD and 80% for NAbs of cases up to 8 months POD | ||
| 520 | |a CONCLUSION: RBD and N protein specific IgG persisted till 240 days POD which correlated with NAb response, irrespective of individual`s symptomatic status indicating overall robust protection against re-infection | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a 240 days | |
| 650 | 4 | |a IgG antibody response | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a neutralizing antibody response | |
| 650 | 4 | |a nucleocapsid | |
| 650 | 4 | |a receptor binding domain | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Spike Glycoprotein, Coronavirus |2 NLM | |
| 650 | 7 | |a spike protein, SARS-CoV-2 |2 NLM | |
| 700 | 1 | |a Kaduskar, Ojas |e verfasserin |4 aut | |
| 700 | 1 | |a Deshpande, Ketki |e verfasserin |4 aut | |
| 700 | 1 | |a Bhatt, Vaishali |e verfasserin |4 aut | |
| 700 | 1 | |a Yadav, Pragya |e verfasserin |4 aut | |
| 700 | 1 | |a Gurav, Yogesh |e verfasserin |4 aut | |
| 700 | 1 | |a Potdar, Varsha |e verfasserin |4 aut | |
| 700 | 1 | |a Khutwad, Kirti |e verfasserin |4 aut | |
| 700 | 1 | |a Vidhate, Shankar |e verfasserin |4 aut | |
| 700 | 1 | |a Salunke, Asha |e verfasserin |4 aut | |
| 700 | 1 | |a Patil, Chetan |e verfasserin |4 aut | |
| 700 | 1 | |a Shingade, Snehal |e verfasserin |4 aut | |
| 700 | 1 | |a Jarande, Kajal |e verfasserin |4 aut | |
| 700 | 1 | |a Tilekar, Bipin |e verfasserin |4 aut | |
| 700 | 1 | |a Salvi, Pavan |e verfasserin |4 aut | |
| 700 | 1 | |a Patsuthe, Sudhir |e verfasserin |4 aut | |
| 700 | 1 | |a Dange, Varsha |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, Sudeep |e verfasserin |4 aut | |
| 700 | 1 | |a Gurav, Shilpa |e verfasserin |4 aut | |
| 700 | 1 | |a Chate, Sadhana |e verfasserin |4 aut | |
| 700 | 1 | |a Abraham, Priya |e verfasserin |4 aut | |
| 700 | 1 | |a Sapkal, Gajanan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases |d 1998 |g 112(2021) vom: 01. Nov., Seite 103-110 |w (DE-627)NLM094730857 |x 1878-3511 |7 nnns |
| 773 | 1 | 8 | |g volume:112 |g year:2021 |g day:01 |g month:11 |g pages:103-110 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ijid.2021.09.024 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 112 |j 2021 |b 01 |c 11 |h 103-110 | ||